Company Overview and News

Hayleys Plantation Sector Ranked Number One in Asia for “Leading HR Practices in Quality Work-life” by the Asia Pacific HRM Congress

The Hayleys Plantations Sector was adjudged number one in Asia for its Quality Work-life HR Practices and was presented the ‘Award for leading HR practices in quality work-life’ at the Asia Pacific HRM Congress. Held in Bangalore India in September, The Asia Pacific HRM Congress Award 2016 recognized the Hayleys Plantation Sector’s exceptional contribution towards driving innovative and game-changing HR practices and initiatives towards the development and uplifting of its direct workforce of 20,000 and extended plantation community of 110,000.

Sri Lanka Economic Summit to discuss struggles to tap agribusiness potential

2016-07-20 lankabusinessonline
‘The Sri Lanka Economic Summit 2016’ organized by the Ceylon Chamber of Commerce has allocated the ‘Session 6’ of the two day event to discuss why the country’s agriculture sector despite the vast promise is still punching below its weight.

‘Why Sri Lanka struggles to tap its agribusiness potential? – Sri Lanka Economic Summit to discuss’

‘The Sri Lanka Economic Summit 2016’ organized by the Ceylon Chamber of Commerce has allocated the ‘Session 6’ of the two day event to discuss why the country’s agriculture sector despite the vast promise is still punching below its weight.

Hayleys Plantations Wins ‘Gold’ at the National HR Excellence Awards 2016, for Uplifting its 20,000 Strong Workforce and their 110,000 Dependents

Ranked the best-performing plantation sector through strategic and groundbreaking HR policies, in the face of industry-wide turbulence Colombo, June 29, 2016:The Hayleys Plantations Sector is the proud ‘Gold Award’ Winner of the National HR Excellence Awards 2016, presented by the Institute of Personal Management Sri Lanka (IPM). This accolade is in recognition of the revolutionary HR practices and policies which the Plantations sector of Hayleys adopted just a couple of years ago, breaking traditional boundaries and industry norms.

Related Articles

SGMO: Sangamo BioSciences and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...